These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3133266)

  • 21. Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion.
    Mauerhoff T; Ketelslegers JM; Lambert AE
    Diabete Metab; 1986 Feb; 12(1):34-8. PubMed ID: 3084315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus.
    Gudat U; Bungert S; Kemmer F; Heinemann L
    Diabet Med; 1998 Mar; 15(3):194-8. PubMed ID: 9545119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up.
    Alvarsson M; Sundkvist G; Lager I; Berntorp K; Fernqvist-Forbes E; Steen L; Orn T; Holberg MA; Kirksaether N; Grill V
    Diabetes Obes Metab; 2008 May; 10(5):421-9. PubMed ID: 17394534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
    Barnett AH; Anderson DM; Shelley S; Morgan R; Owens DR
    Diabetes Obes Metab; 2004 Mar; 6(2):104-13. PubMed ID: 14746575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs.
    Mohan V; Snehalatha C; Ramachandran A; Viswanathan M
    J Assoc Physicians India; 1990 Aug; 38(8):537-41. PubMed ID: 2123183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of glibenclamide on insulin secretion at normal glucose concentrations.
    Riefflin A; Ayyagari U; Manley SE; Holman RR; Levy JC
    Diabetologia; 2015 Jan; 58(1):43-9. PubMed ID: 25297572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents.
    Iavicoli M; Cucinotta D; De Mattia G; Lunetta M; Morsiani M; Pontiroli AE; Pozza G
    Diabet Med; 1988 Dec; 5(9):849-55. PubMed ID: 2976646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanism of action of combined administration of glibenclamide and insulin in type II diabetics with secondary failure of oral treatment].
    Schmidt FH; Klujko J; Kühnle HF; Reiter J
    Klin Wochenschr; 1986 Oct; 64(20):1021-3. PubMed ID: 3097384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    van der Wal PS; Heine RJ
    Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a gel forming dietary fiber, guar gum, on the absorption of glibenclamide and metabolic control and serum lipids in patients with non-insulin-dependent (type 2) diabetes.
    Uusitupa M; Södervik H; Silvasti M; Karttunen P
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):153-7. PubMed ID: 2110937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus.
    Davidson JA; Scheen AJ; Howlett HC
    Drug Saf; 2004; 27(15):1205-16. PubMed ID: 15588116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy.
    Lins PE; Lundblad S; Persson-Trotzig E; Adamson U
    Acta Med Scand; 1988; 223(2):171-9. PubMed ID: 3126626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.